Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly To Settle Additional Zyprexa Liability Cases, Will Pay Up To $500 Million

Executive Summary

Lilly will pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of risks associated with the atypical antipsychotic Zyprexa (olanzapine), the firm announced Jan. 4

You may also be interested in...



Lilly’s Zyprexa Gets MedGuide, Labeling Update And New Indication

Antipsychotic clears FDA for treatment-resistant depression in combination with fluoxetine, as does combo pill Symbyax.

Lilly’s legal woes continue

Utah Attorney General files suit in state court May 17 against Lilly to recover Medicaid funds it says were spent on "inappropriate and medically unnecessary doses of Zyprexa" as a result of Lilly's marketing of the atypical antipsychotic for off-label uses like Alzheimer's disease, geriatric dementia and Tourette's syndrome. Utah AG also alleges Lilly marketed Zyprexa (olanzapine), which is approved for schizophrenia and bipolar disorder, "as being medically superior to other antipsychotic medication" and not requiring blood tests or other monitoring, which the firm knew to be false because an increased risk of hyperglycemia, weight gain and diabetes associated with the drug would necessitate medical monitoring and blood tests. The state claims it is entitled to restitution for unnecessary prescriptions and the resulting cost of care, as well as civil penalties and legal fees. Zyprexa has been the subject of extensive legal action. In January, Lilly announced it would pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of Zyprexa risks (1"The Pink Sheet" Jan. 8, 2007, p. 16)...

Lilly’s legal woes continue

Utah Attorney General files suit in state court May 17 against Lilly to recover Medicaid funds it says were spent on "inappropriate and medically unnecessary doses of Zyprexa" as a result of Lilly's marketing of the atypical antipsychotic for off-label uses like Alzheimer's disease, geriatric dementia and Tourette's syndrome. Utah AG also alleges Lilly marketed Zyprexa (olanzapine), which is approved for schizophrenia and bipolar disorder, "as being medically superior to other antipsychotic medication" and not requiring blood tests or other monitoring, which the firm knew to be false because an increased risk of hyperglycemia, weight gain and diabetes associated with the drug would necessitate medical monitoring and blood tests. The state claims it is entitled to restitution for unnecessary prescriptions and the resulting cost of care, as well as civil penalties and legal fees. Zyprexa has been the subject of extensive legal action. In January, Lilly announced it would pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of Zyprexa risks (1"The Pink Sheet" Jan. 8, 2007, p. 16)...

Related Content

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel